USE OF ONDANSETRON FOR CONTROL OF PROJECTILE VOMITING IN PATIENTS WITH NEUROSURGICAL TRAUMA - 2 CASE-REPORTS

被引:9
作者
KLEINERMAN, KB
DEPPE, SA
SARGENT, AI
机构
[1] MERCY HOSP,DEPT MED,DIV CRIT CARE MED,TRAUMA ICU,1400 LOCUST ST,PITTSBURGH,PA 15219
[2] MERCY HOSP,DEPT ANESTHESIOL,PITTSBURGH,PA 15219
[3] MERCY HOSP,DEPT PHARM,PITTSBURGH,PA 15219
关键词
D O I
10.1177/106002809302700505
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe two cases of projectile vomiting that were treated successfully with ondansetron in patients with neurosurgical trauma. Causes and pharmacologic treatments for nausea and emesis are also discussed. DATA SOURCES: Patient data and literature citations from published case reports, review articles, and clinical research reports as identified by MEDLINE. DATA SYNTHESIS: Ondansetron, a potent and highly selective antagonist of serotonin at the 5-HT3 (subtype 3)-receptor, possesses potent antiemetic effects. It has not been associated with the extrapyramidal adverse effects seen with traditional antiemetics. The occurrence of extrapyramidal reactions may limit the usefulness of conventional antiemetics in neurosurgical patients because such agents interfere with serial mental status examinations and lower the seizure threshold. Therefore, ondansetron may be preferable in this patient population. Two patients with head trauma and projectile vomiting were treated successfully with ondansetron following treatment failure with prochlorperazine. These represent the first reported cases of efficacious treatment with ondansetron in neurosurgical trauma patients. CONCLUSIONS: Ondansetron may be the preferred agent for controlling nausea and vomiting in patients with neurosurgical trauma. Controlled clinical trials are needed to evaluate its safety and efficacy in this patient population.
引用
收藏
页码:566 / 568
页数:3
相关论文
共 10 条
[1]  
BODNER M, 1991, ANESTH ANALG, V73, P250
[2]  
CHAFFEE BJ, 1991, CLIN PHARMACY, V10, P430
[3]   PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST [J].
CUNNINGHAM, D ;
POPLE, A ;
FORD, HT ;
HAWTHORN, J ;
GAZET, JC ;
CHALLONER, T ;
COOMBES, RC .
LANCET, 1987, 1 (8548) :1461-1463
[4]  
GRAVES T, 1990, DICP ANN PHARM S, V24, pS1
[5]   THE DISTRIBUTION OF SPECIFIC BINDING OF THE 5-HT3 RECEPTOR LIGAND [H-3] GR65630 IN RAT-BRAIN USING QUANTITATIVE AUTORADIOGRAPHY [J].
KILPATRICK, GJ ;
JONES, BJ ;
TYERS, MB .
NEUROSCIENCE LETTERS, 1988, 94 (1-2) :156-160
[6]  
KRIS MG, 1983, NEW ENGL J MED, V309, P433
[7]  
LARIJANI GE, 1991, ANESTH ANALG, V73, P246
[8]  
LEESER J, 1991, ANESTH ANALG, V72, P751
[9]   COMPARISON OF THE 5-HYDROXYTRYPTAMINE3 (SEROTONIN) ANTAGONIST ONDANSETRON (GR-38032F) WITH HIGH-DOSE METOCLOPRAMIDE IN THE CONTROL OF CISPLATIN-INDUCED EMESIS [J].
MARTY, M ;
POUILLART, P ;
SCHOLL, S ;
DROZ, JP ;
AZAB, M ;
BRION, N ;
PUJADELAURAINE, E ;
PAULE, B ;
PAES, D ;
BONS, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (12) :816-821
[10]   GR38032F, A 5HT3 RECEPTOR ANTAGONIST, IN THE PROPHYLAXIS OF ACUTE CISPLATIN-INDUCED NAUSEA AND VOMITING [J].
MARTY, M ;
DROZ, JP ;
POUILLART, P ;
PAULE, B ;
BRION, N ;
BONS, J .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (06) :389-391